GlassScriptPhysician profile
Mark D Porta
NPI 1275890436
$4,913.45
in general payments reported to CMS, 2019-2025
34 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $447 · 2021: $423 · 2022: $674 · 2023: $807 · 2024: $939 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.38 | 2020-2025 | |
| Boston Scientific Corporation | $635.74 | 2019-2024 | |
| Janssen Biotech, INC. | $635.31 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $488.99 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $457.23 | 2020-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $357.16 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $346.90 | 2020-2025 | Entyvio, Gattex |
| Genzyme Corporation | $137.73 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $101.42 | 2019-2022 | |
| Madrigal Pharmaceuticals | $87.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $68.57 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $65.08 | 2023-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $61.54 | 2024-2025 | Iqirvo, Bylvay |
| Qol Medical, LLC | $61.46 | 2023-2025 | Sucraid |
| Pfizer INC. | $57.42 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $52.52 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $52.13 | 2022-2023 | Terlivaz |
| Gilead Sciences, INC. | $48.24 | 2020-2025 | |
| Redhill Biopharma INC. | $48.12 | 2022-2023 | Talicia |
| Braintree Laboratories, INC. | $47.91 | 2020-2024 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $38.74 | 2024-2025 | Dupixent |
| Daiichi Sankyo INC. | $38.42 | 2019-2022 | |
| Amgen INC. | $34.36 | 2022-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $26.95 | 2025 | Omvoh |
| Ambu INC. | $24.64 | 2020 | |
| Olympus America INC. | $19.83 | 2019 | |
| Echosens North America, INC. | $19.82 | 2023 | Fibroscan |
| Apollo Endosurgery US INC | $19.15 | 2019 | |
| Aimmune Therapeutics, INC. | $18.97 | 2025 | Zenpep |
| Novo Nordisk INC | $14.69 | 2025 | Wegovy |
| Shire North American Group INC | $13.75 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.10 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,328.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Porta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.